专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110293525A1 TUMOR STEM CELLS 审中-公开
标题翻译：肿瘤干细胞
公开(公告)号：US20110293525A1
公开(公告)日：2011-12-01
申请号：US13118760
申请日：2011-05-31
申请人： James A. Radosevich
发明人： James A. Radosevich
IPC分类号： A61K49/00 , C12Q1/02 , A61P35/00 , C12Q1/32 , C12Q1/48 , C12Q1/26 , C12N5/095 , G01N33/53
CPC分类号： C12N5/0695 , C12N5/0093 , C12N2501/03 , C12N2506/23 , C12N2506/246 , C12N2506/30 , G01N33/5011
摘要： Tumor stem cells can be obtained by culturing a tumor cell population, and exposing the cultured tumor cell population to free radicals. In certain embodiments, the free radical agent can be a nitric oxide (NO) donor. In one embodiment, the free radical agent can be Diethylenetriamine NONOate (DETA NONOate) or agents that constitutively increase cellular nitric oxide, such as phosphodiesterase inhibitors or L-arginine, or agents that increase NO synthase in the population. The methods can further include inducing stem cells present in the population to expand and/or inducing dedifferentiation of tumor cells into tumor stem cells. Additionally, the present invention provides methods of selecting stem cells from a tumor cell population. Another aspect provides methods of screening for anti-tumor stem cell teherapeutic compounds by providing high nitric oxide (HNO) tumor cells, exposing the HNO cells to at least one compound, assessing one or more indicators of HNO cell health and determining toxicity of the compound to HNO tumor cells.
摘要翻译：可以通过培养肿瘤细胞群体并将培养的肿瘤细胞群暴露于自由基来获得肿瘤干细胞。在某些实施方案中，自由基剂可以是一氧化氮（NO）供体。在一个实施方案中，自由基剂可以是二亚乙基三胺NONOate（DETA NONOate）或组成型增加细胞一氧化氮的试剂，例如磷酸二酯酶抑制剂或L-精氨酸，或增加群体中NO合酶的试剂。所述方法还可以包括诱导存在于群体中的干细胞以扩增和/或诱导肿瘤细胞去分化成肿瘤干细胞。另外，本发明提供从肿瘤细胞群体中选择干细胞的方法。另一方面提供了通过提供高一氧化氮（HNO）肿瘤细胞，将HNO细胞暴露于至少一种化合物来评估抗肿瘤干细胞治疗性化合物的方法，评估一种或多种HNO细胞健康指标和测定化合物的毒性到HNO肿瘤细胞。

2. 发明申请

US20110206781A1 METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH 审中-公开
标题翻译：调节HEMATOPOIETIC干细胞生长的方法
公开(公告)号：US20110206781A1
公开(公告)日：2011-08-25
申请号：US12994527
申请日：2009-05-28
申请人： Leonard I. Zon , Trista E. North , Wolfram Goessling
发明人： Leonard I. Zon , Trista E. North , Wolfram Goessling
IPC分类号： A61K33/00 , C12N5/0789 , A61K31/197 , A61K31/517 , A61K31/138 , A61K31/4418 , A61K31/7048 , A61K31/198 , A61K31/295 , A61K31/165 , A61K31/4985 , A61K31/137 , A61K31/44 , A61K31/353 , A61K31/216 , A61P7/00
CPC分类号： A61K31/00 , A61K31/04 , C12N5/0647 , C12N2501/03 , C12N2506/02 , C12N2506/11 , C12N2506/45
摘要： Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells (HSC) and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro, ex vivo and/or in vivo. Also described are methods, compositions and kits related to making an expanded population of HSC and methods, compositions and kits related to using the expanded population of HSC. For example, HSC growth may be enhanced by contacting the nascent stem cells or HSC with an agent that stimulates the nitric oxide signaling pathway.
摘要翻译：本文描述了与操纵造血干细胞（HSC）相关的方法，组合物和试剂盒，更具体地涉及与体外，离体和/或体内增加造血干细胞数量有关的方法，组合物和试剂盒。还描述了与制造HSC的扩大群体相关的方法，组合物和试剂盒以及与使用HSC的扩展群体相关的方法，组合物和试剂盒。例如，可以通过使新生干细胞或HSC与刺激一氧化氮信号通路的药物接触来增强HSC生长。

3. 发明授权

US06630480B1 Methods of treating leukemia 有权
标题翻译：白血病治疗方法
公开(公告)号：US06630480B1
公开(公告)日：2003-10-07
申请号：US09536459
申请日：2000-03-28
申请人： Henriette Gourdeau , Francis J. Giles
发明人： Henriette Gourdeau , Francis J. Giles
IPC分类号： A61K31505
CPC分类号： A61K31/675 , A61K31/506 , A61K31/70 , A61K31/704 , A61K38/13 , A61K38/1816 , A61K38/193 , A61K38/2013 , A61K38/202 , A61K38/212 , A61K38/32 , A61K39/39541 , A61K45/06 , A61K2035/124 , C12N5/0644 , C12N2501/03 , C12N2501/145 , A61K31/505 , A61K38/19 , A61K2300/00 , A61K38/20
摘要： The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and an hydroxy protecting group; and wherein said compound is substantially in the form of the (−) enantiomer.
摘要翻译：本发明提供了一种用于治疗白血病，更特别是急性骨髓性白血病（AML）的宿主的新方法，其包括向宿主施用治疗有效量的具有式I的化合物：其中B为胞嘧啶或5-氟胞嘧啶，R为选自包括H，单磷酸酯，二磷酸酯，三磷酸酯，被C 1-6烷基取代的羰基，C 2-6烯基，C 2-6炔基，C 6-10芳基，并且其中每个R c独立地选自H，C 1 C6烷基，C2-6烯基，C2-6炔基和羟基保护基; 并且其中所述化合物基本上为（ - ）对映异构体的形式。

4. 发明申请

US20130252236A1 TUMOR STEM CELLS 审中-公开
标题翻译：肿瘤干细胞
公开(公告)号：US20130252236A1
公开(公告)日：2013-09-26
申请号：US13630774
申请日：2012-09-28
申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
发明人： James A. Radosevich
IPC分类号： C12N5/095
CPC分类号： C12N5/0695 , C12N5/0093 , C12N2501/03 , C12N2506/23 , C12N2506/246 , C12N2506/30 , G01N33/5011
摘要： Tumor stem cells can be obtained by culturing a tumor cell population, and exposing the cultured tumor cell population to free radicals. In certain embodiments, the free radical agent can be a nitric oxide (NO) donor. In one embodiment, the free radical agent can be Diethylenetriamine NONOate (DETA NONOate) or agents that constitutively increase cellular nitric oxide, such as phosphodiesterase inhibitors or L-arginine, or agents that increase NO synthase in the population. The methods can further include inducing stem cells present in the population to expand and/or inducing dedifferentiation of tumor cells into tumor stem cells. Additionally, the present invention provides methods of selecting stem cells from a tumor cell population. Another aspect provides methods of screening for anti-tumor stem cell teherapeutic compounds by providing high nitric oxide (HNO) tumor cells, exposing the HNO cells to at least one compound, assessing one or more indicators of HNO cell health and determining toxicity of the compound to HNO tumor cells.
摘要翻译：可以通过培养肿瘤细胞群体并将培养的肿瘤细胞群暴露于自由基来获得肿瘤干细胞。在某些实施方案中，自由基剂可以是一氧化氮（NO）供体。在一个实施方案中，自由基剂可以是二亚乙基三胺NONOate（DETA NONOate）或组成型增加细胞一氧化氮的试剂，例如磷酸二酯酶抑制剂或L-精氨酸，或增加群体中NO合酶的试剂。所述方法还可以包括诱导存在于群体中的干细胞以扩增和/或诱导肿瘤细胞去分化成肿瘤干细胞。另外，本发明提供从肿瘤细胞群体中选择干细胞的方法。另一方面提供了通过提供高一氧化氮（HNO）肿瘤细胞，将HNO细胞暴露于至少一种化合物来评估抗肿瘤干细胞治疗性化合物的方法，评估一种或多种HNO细胞健康指标和测定化合物的毒性到HNO肿瘤细胞。

5. 发明申请

US20060040885A1 Bioprosthetic heart valves 审中-公开
公开(公告)号：US20060040885A1
公开(公告)日：2006-02-23
申请号：US11208331
申请日：2005-08-19
申请人： Nalini Rajamannan
发明人： Nalini Rajamannan
IPC分类号： A61K48/00 , A61K31/5377
CPC分类号： G01N33/5011 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/5377 , A61K31/7052 , A61K38/44 , A61K48/005 , A61K48/0075 , A61L27/3625 , A61L27/3645 , A61L27/3683 , A61L27/3695 , A61L27/38 , A61L27/507 , C12N5/0602 , C12N15/86 , C12N2501/03 , C12N2501/70 , C12N2510/00 , C12N2710/10343 , C12Y114/13039 , G01N33/5008 , G01N33/5061 , G01N33/5064 , G01N33/5088 , A61K2300/00
摘要： The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration, thrombosis, and calcification, (2) treating carcinoid heart disease, (3) identifying inhibitors of heart valve degeneration, thrombosis, and calcification, and (4) determining the safety of drugs.

6. 发明授权

US06589759B1 Compositions and methods for producing platelets and/or proplatelets from megakaryocytes 失效
标题翻译：用于从巨核细胞产生血小板和/或血小板的组合物和方法
公开(公告)号：US06589759B1
公开(公告)日：2003-07-08
申请号：US09937336
申请日：2001-12-05
申请人： Joseph Loscalzo , Elisabeth M. Battinelli
发明人： Joseph Loscalzo , Elisabeth M. Battinelli
IPC分类号： C12Q134
CPC分类号： C12N5/0644 , A61K31/198 , A61K31/401 , A61K31/573 , A61K35/19 , A61K38/06 , A61K38/196 , A61K45/06 , C12N2501/03 , C12N2501/145 , A61K2300/00
摘要： The present invention describes novel compositions and methods to enhance the in vitro and in vivo production of platelets and/or proplatelets from megakaryocytes. The present invention describes compositions comprising megakaryocytes, nitric oxide donors (i.e. compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are substrates for nitric oxide synthase), and, optionally, at least one thrombopoiesis stimulating factor. The thrombopoiesis stimulating factor is preferably thrombopoietin. The nitric oxide donor is preferable S-nitrosoglutathione. The present invention also describes compositions comprising at least one nitric oxide donor and at least one thrombopoiesis stimulating factor. The present invention also provides methods for treating and/or preventing blood platelet disorders, and for producing platelets and/or proplatelets in vitro and in vivo. The compounds and/or compositions of the present invention can be provided in the form of a pharmaceutical kit.
摘要翻译：本发明描述了增强来自巨核细胞的血小板和/或血小板的体外和体内产生的新型组合物和方法。本发明描述了包含巨核细胞，一氧化氮供体（即捐赠，转移或释放一氧化氮的化合物，提高内源性内源性舒张因子水平，刺激一氧化氮的内源性合成或一氧化氮合酶的底物）的组合物，任选地，至少一种血小板生成刺激因子。血小板生成刺激因子优选为血小板生成素。一氧化氮供体优选S-亚硝基谷胱甘肽。本发明还描述了包含至少一种一氧化氮供体和至少一种血小板生成刺激因子的组合物。本发明还提供了用于治疗和/或预防血小板疾病和用于在体外和体内产生血小板和/或血小板的方法。本发明的化合物和/或组合物可以以药物试剂盒的形式提供。

7. 发明申请

US20020159983A1 Bioprosthetic heart valves 有权
标题翻译：生物假体心脏瓣膜
公开(公告)号：US20020159983A1
公开(公告)日：2002-10-31
申请号：US10032123
申请日：2001-12-21
申请人： Mayo Foundation for Medical Education and Research , a Minnesota corporation
发明人： Nalini M. Rajamannan
IPC分类号： A61K048/00 , C12N005/08 , C12N015/85
CPC分类号： G01N33/5011 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/5377 , A61K31/7052 , A61K38/44 , A61K48/005 , A61K48/0075 , A61L27/3625 , A61L27/3645 , A61L27/3683 , A61L27/3695 , A61L27/38 , A61L27/507 , C12N5/0602 , C12N15/86 , C12N2501/03 , C12N2501/70 , C12N2510/00 , C12N2710/10343 , C12Y114/13039 , G01N33/5008 , G01N33/5061 , G01N33/5064 , G01N33/5088 , A61K2300/00
摘要： The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration, thrombosis, and calcification, (2) treating carcinoid heart disease, (3) identifying inhibitors of heart valve degeneration, thrombosis, and calcification, and (4) determining the safety of drugs.
摘要翻译：本发明提供了与心脏瓣膜相关的方法和材料以及瓣膜性心脏病的治疗。具体而言，本发明提供非鼠类心脏瓣膜细胞和心脏瓣膜尖端以及制造心脏瓣膜的方法。本发明还提供了（1）减慢心脏瓣膜变性，血栓形成和钙化的方法和材料，（2）治疗类癌心脏病，（3）鉴别心脏瓣膜变性抑制剂，血栓形成和钙化，以及（4）确定药物安全

8. 发明申请

US20170368104A1 INDUCTION OF TOLERANCE IN LUNG ALLOGRAFT TRANSPLANTATION 审中-公开
公开(公告)号：US20170368104A1
公开(公告)日：2017-12-28
申请号：US15694544
申请日：2017-09-01
申请人： Washington University
发明人： Alexander Sasha Krupnick , Daniel Kreisel , Andrew Gelman
IPC分类号： A61K35/42 , C12N5/071 , A61K33/00 , A61K35/17 , A61K38/21 , A61K35/12
CPC分类号： A61K35/42 , A61K33/00 , A61K35/17 , A61K38/217 , A61K2035/122 , C12N5/0688 , C12N2501/03 , C12N2501/24
摘要： The present disclosure relates to methods of inducing tolerance to lung allograft transplantation. These methods comprise increasing suppressor CD8+ T cells and/or suppressing deleterious CD8+ and CD4+ T cells.

9. 发明申请

US20170175084A1 TUMOR STEM CELLS 审中-公开
公开(公告)号：US20170175084A1
公开(公告)日：2017-06-22
申请号：US15452138
申请日：2017-03-07
申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
发明人： James A. RADOSEVICH
IPC分类号： C12N5/095 , C12N5/00
CPC分类号： C12N5/0695 , C12N5/0093 , C12N2501/03 , C12N2506/23 , C12N2506/246 , C12N2506/30 , G01N33/5011
摘要： Tumor stem cells can be obtained by culturing a tumor cell population, and exposing the cultured tumor cell population to free radicals. In certain embodiments, the free radical agent can be a nitric oxide (NO) donor. In one embodiment, the free radical agent can be Diethylenetriamine NONOate (DETA NONOate) or agents that constitutively increase cellular nitric oxide, such as phosphodiesterase inhibitors or L-arginine, or agents that increase NO synthase in the population. The methods can further include inducing stem cells present in the population to expand and/or inducing dedifferentiation of tumor cells into tumor stem cells. Additionally, the present invention provides methods of selecting stem cells from a tumor cell population. Another aspect provides methods of screening for anti-tumor stem cell teherapeutic compounds by providing high nitric oxide (HNO) tumor cells, exposing the HNO cells to at least one compound, assessing one or more indicators of HNO cell health and determining toxicity of the compound to HNO tumor cells.

10. 发明授权

US07531575B2 Method of modulating cellular activity and agents useful for same 失效
标题翻译：调节细胞活性的方法和对其有用的试剂
公开(公告)号：US07531575B2
公开(公告)日：2009-05-12
申请号：US10697655
申请日：2003-10-31
申请人： Michael Weller , Wolfgang Wick , Jörg Wischhusen , Michael Platten
发明人： Michael Weller , Wolfgang Wick , Jörg Wischhusen , Michael Platten
IPC分类号： A61K31/195 , A61K43/00
CPC分类号： A61K31/15 , C12N5/0622 , C12N2501/03 , C12N2501/24 , Y10S514/903
摘要： Described is a rational design of therapeutic and/or prophylactic methods of treating conditions characterized by aberrant or otherwise unwanted microglial cell functioning and rational design methods for treating a range of neurological disorders which are characterized by nitric oxide induced neuronal damage.
摘要翻译：描述了治疗和/或预防方法的合理设计，所述治疗和/或预防方法以特征在于异常或其他不希望的小神经胶质细胞功能和用于治疗以一氧化氮诱导的神经元损伤为特征的一系列神经障碍的合理设计方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式